United States · Platforms & data · MarketBeat
Syncona H1 Earnings Call Highlights
Detailed summary
Syncona (LON:SYNC) reported a 3% increase in net asset value in its interim results, supported by a 4.7% return from its life sciences portfolio and a higher valuation for deferred consideration linked to portfolio company Beacon Therapeutics. The life sciences portfolio was valued at £921 million.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)
